- MIRA (MIRA, Financial) reports up to 30% weight loss and reduction in cravings from SKNY-1 in animal studies.
- SKNY-1 targets obesity and nicotine addiction markets, boasting a combined opportunity of over $200 billion.
- Development plans include progressing towards IND-enabling studies post-acquisition of SKNY Pharmaceuticals.
MIRA Pharmaceuticals, Inc. (MIRA) has revealed significant advancements in its preclinical studies of SKNY-1, an oral therapeutic candidate under a definitive acquisition agreement. In recent animal model applications, the drug exhibited a remarkable 30% weight reduction alongside a reversal of nicotine and high-calorie food cravings in zebrafish models within six days.
The key findings of the study highlight notable metabolic improvements without any muscle mass loss, normalization of liver fat and cholesterol levels, and reduced appetite and nicotine-seeking behaviors. These outcomes were achieved through the selective modulation of CB1 receptors and activation of CB2 receptors, maintaining a favorable safety profile. SKNY-1 is designed to serve as an oral alternative to GLP-1 injectables, addressing common limitations such as GI discomfort and preservation of muscle mass in current obesity and smoking cessation treatments.
Targeting a combined global market exceeding $200 billion, MIRA plans to push SKNY-1 forward into IND-enabling studies following the finalization of its acquisition of SKNY Pharmaceuticals, Inc. This advancement places SKNY-1 as a potential disruptive oral treatment in the weight loss and smoking cessation sectors, addressing significant unmet medical needs while minimizing central nervous system side effects.
About MIRA Pharmaceuticals, Inc.: MIRA is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company is committed to addressing significant unmet medical needs through its innovative pipeline of oral drug candidates.
